NewLink Genetics Corporation Securities Fraud Class Action

VIEW COMPLAINT

Please complete this form and list your purchase and sale transaction(s) for NewLink Genetics Corporation (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016, inclusive (the “Class Period”):

You may also contact Jon Naji, Esq. at 484-270-1453, or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

Information Sheet

* Denotes required field

First Name *

Last Name *

Email *

Country

City

State\Province

Zip\Postal Code

Country Prefix

Phone Number

Phone Type

Purchase(s)

+ Additional Purchases

Sale(s)

+ Additional Sales

Date

# of Shares

Price per Share

Date

Principal Amount

Amount Paid

Series or CUSIP

Date

# of Contracts

Price per Contract

Exercise Price

Expiration Date

Did you purchase shares of NewLink Genetics Corporation (2016) prior to the Class Period?

Yes

Are you a current or former employee of NewLink Genetics Corporation (2016)?

Yes

The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.

I agree to the KTMC
disclaimer

Yes

I would like to receive
new case alerts by email

Yes

Submit Your Information

COMPANY	NewLink Genetics Corporation
COURT	United States District Court for the Southern District of New York
CASE NUMBER	16-cv-03545
JUDGE	The Hon. William H. Pauley III
CLASS PERIOD	September 17, 2013 and May 9, 2016
SECURITY TYPE	All Securities

Case Background:

On May 12, 2016, the initial complaint in this securities class action was filed against NewLink Genetics Corporation (“NewLink” or the “Company”), and certain of NewLink’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. The Complaint alleges that throughout the class period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients; and (ii) as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

Defendants filed a Motion to Dismiss the second amended complaint (the “Amended Complaint”) on July 31, 2018. On February 13, 2019, the Court issued an Order granting Defendants' Motion to Dismiss the Amended Complaint. Lead Plaintiffs filed a Notice appealing the dismissal on March 14, 2019. On July 13, 2020, the Court of Appeals affirmed in part and reversed in part the District Court's dismissal Order. The case was remanded back to the District Court for further proceedings. On April 2, 2021, the District Court issued an Order preliminarily approving Settlement and entered a Final Judgment on September 22, 2021. This action has concluded.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.